Ono Pharmaceutical (OTCMKTS:OPHLF) Shares Gap Down – What’s Next?

Shares of Ono Pharmaceutical Co. (OTCMKTS:OPHLF) gapped down prior to trading on Monday. The stock had previously closed at $16.11, but opened at $13.6650. Ono Pharmaceutical shares last traded at $13.6650, with a volume of 686 shares.

Wall Street Analyst Weigh In

Separately, Zacks Research downgraded shares of Ono Pharmaceutical from a “strong-buy” rating to a “hold” rating in a report on Friday, September 4th. One research analyst has rated the stock with a Hold rating, According to data from MarketBeat.com, Ono Pharmaceutical presently has an average rating of “Hold”.

Ono Pharmaceutical Stock Down 5.0%

The firm has a market capitalization of $7.19 billion, a PE ratio of 14.57 and a beta of 0.33. The business’s 50 day simple moving average is $14.97 and its 200 day simple moving average is $14.61. The company has a current ratio of 3.28, a quick ratio of 2.86 and a debt-to-equity ratio of 0.08.

Ono Pharmaceutical Company Profile

Ono Pharmaceutical Co, Ltd. is a Japanese research-driven pharmaceutical company headquartered in Osaka. The company discovers, develops, manufactures and markets prescription medicines, with a focus on oncology, immunology, neurology and other specialty-care areas. Its activities include both internally developed products and collaborations with pharmaceutical and biotechnology companies worldwide.

Ono is best known internationally for Opdivo (nivolumab), an immune checkpoint inhibitor developed in collaboration with Bristol Myers Squibb and used to treat multiple types of cancer.